Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Septic Shock - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Septic Shock - Pipeline Review, H2 2016', provides an overview of the Septic Shock pipeline landscape. The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Septic Shock - The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects - The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Septic Shock Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Septic Shock - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Septic Shock Overview 9 Therapeutics Development 10 Pipeline Products for Septic Shock - Overview 10 Pipeline Products for Septic Shock - Comparative Analysis 11 Septic Shock - Therapeutics under Development by Companies 12 Septic Shock - Therapeutics under Investigation by Universities/Institutes 14 Septic Shock - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Septic Shock - Products under Development by Companies 19 Septic Shock - Products under Investigation by Universities/Institutes 20 Septic Shock - Companies Involved in Therapeutics Development 21 Adrenomed AG 21 Ferring International Center S.A. 22 Huons Co., Ltd. 23 InflaRx GmbH 24 Inotrem S.A. 25 Lixte Biotechnology Holdings, Inc. 26 Noxxon Pharma AG 27 Octapharma AG 28 Orion Oyj 29 Peptinov SAS 30 Pharmazz, Inc. 31 Spider Biotech 32 Takeda Pharmaceutical Company Limited 33 Therashock, LLC 34 ViiV Healthcare Limited 35 XImmune AB 36 Septic Shock - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 3K3A-APC - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 adrecizumab - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AM-12 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Aspidasept - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 BC-1215 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 BMS-936559 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 BTZO-2 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Drug for Sepsis and Septic Shock - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 HBN-1 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 HBN-3 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 HBN-4 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 HU-003 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 IFX-1 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 L-257 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 LB-100 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 levosimendan - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 M-6229 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Motrem - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 NOXD-21 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 PMZ-2010 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 pooled plasma (human) - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 R-190 - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 SB-056 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 selepressin - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 SP-14 - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 SP-9 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Septic Shock - Dormant Projects 83 Septic Shock - Discontinued Products 85 Septic Shock - Product Development Milestones 86 Featured News & Press Releases 86 Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock 86 Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 86 Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody 87 Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan 88 Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients 89 Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock 90 Appendix 91 Methodology 91 Coverage 91 Secondary Research 91 Primary Research 91 Expert Panel Validation 91 Contact Us 91 Disclaimer 92
List of Tables
Number of Products under Development for Septic Shock, H2 2016 10 Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Comparative Analysis by Unknown Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Septic Shock - Pipeline by Adrenomed AG, H2 2016 21 Septic Shock - Pipeline by Ferring International Center S.A., H2 2016 22 Septic Shock - Pipeline by Huons Co., Ltd., H2 2016 23 Septic Shock - Pipeline by InflaRx GmbH, H2 2016 24 Septic Shock - Pipeline by Inotrem S.A., H2 2016 25 Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 26 Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016 27 Septic Shock - Pipeline by Octapharma AG, H2 2016 28 Septic Shock - Pipeline by Orion Oyj, H2 2016 29 Septic Shock - Pipeline by Peptinov SAS, H2 2016 30 Septic Shock - Pipeline by Pharmazz, Inc., H2 2016 31 Septic Shock - Pipeline by Spider Biotech, H2 2016 32 Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 33 Septic Shock - Pipeline by Therashock, LLC, H2 2016 34 Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016 35 Septic Shock - Pipeline by XImmune AB, H2 2016 36 Assessment by Monotherapy Products, H2 2016 37 Number of Products by Stage and Target, H2 2016 39 Number of Products by Stage and Mechanism of Action, H2 2016 41 Number of Products by Stage and Route of Administration, H2 2016 43 Number of Products by Stage and Molecule Type, H2 2016 45 Septic Shock - Dormant Projects, H2 2016 83 Septic Shock - Dormant Projects (Contd..1), H2 2016 84 Septic Shock - Discontinued Products, H2 2016 85
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.